gemcitabine + docetaxel

Gemcitabine + docetaxel is a combination chemotherapy regimen used primarily for the treatment of various cancers, including soft tissue sarcoma and bladder cancer. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and inhibiting ribonucleotide reductase, leading to masked chain termination and apoptosis in malignant cells. Docetaxel is a taxoid antineoplastic agent that stabilizes microtubules, preventing their depolymerization, which disrupts mitosis and leads to cell death. The combination leverages complementary mechanisms—gemcitabine induces cell cycle arrest while docetaxel promotes cell death—resulting in synergistic anti-tumor effects[2][5][6][8]. This regimen can be administered intravenously or intravesically (directly into the bladder) depending on indication[1][3].

Brand names

GemzarTaxotere

Other names

GD (for the combination)gemcitabine-docetaxel